The U.S. Food and Drug Administration approved Merck & Co.'s drug Lipfendra, the first oral PCSK9 inhibitor pill for lowering cholesterol [1].
This approval marks a significant shift in cardiovascular care by replacing required injections with a pill. For patients with hypercholesterolemia, the availability of a non-injectable option may increase treatment adherence and accessibility to advanced cholesterol-lowering therapies [4, 5].
Lipfendra, also known as enlicitide decanoate, is specifically approved for adults with hypercholesterolemia [3]. The drug targets the proprotein convertase subtilisin/kexin type 9 (PCSK9) protein, which plays a critical role in how the liver clears low-density lipoprotein cholesterol (LDL-C) from the blood [2, 3].
Previous PCSK9 inhibitors required subcutaneous injections, often administered in a clinical setting or via home-injection kits. By delivering this mechanism through an oral tablet, Merck provides a more convenient alternative for those who cannot tolerate or avoid needles [4, 5].
The FDA announced the approval on a Thursday in July 2026 [2, 3]. The decision follows clinical evaluations of the drug's ability to reduce LDL-C levels in adult populations [3].
Merck has developed the drug to expand the toolkit for managing high cholesterol beyond traditional statins and injectable biologics [4]. The company intends for Lipfendra to serve as a primary option for patients needing potent LDL-C reduction without the burden of injectable medication [5].
“The FDA approved Merck & Co.'s drug Lipfendra, the first oral PCSK9 inhibitor pill for lowering cholesterol.”
The transition from injectable to oral PCSK9 inhibitors removes a major psychological and physical barrier for patients with chronic high cholesterol. By simplifying the administration of a potent class of drugs, this approval likely increases the total number of patients who will maintain their treatment regimens, potentially reducing the long-term incidence of cardiovascular events across the adult population.
